Drug induced tendon injury
Authors:
Štefan Alušík 1; Zoltán Paluch 2
Authors‘ workplace:
Katedra vnitřního lékařství IPVZ, Praha
1; Ústav farmakologie 2. LF UK, Praha
2
Published in:
Vnitř Lék 2017; 63(12): 967-971
Category:
Reviews
Overview
Tendon injury belongs to the less known side effects of some drugs, reported until recently only for glucocorticoids and fluoroquinolones. To date, some other classes of drugs such as statins, aromatase inhibitors, anabolic steroids, potentially causing tendon injury, have been added to the list. The authors discuss the most common clinical presentations, diagnosis, and management as well as latest experimental data regarding this issue. The most often, the Achilles tendon is affected, however, nearly every tendon of the entire body may be affected. Tendon rupture or drug induced tendinopathy should be strongly considered in those who have a tendon injury and have recently taken these drugs.
Key words:
anabolic steroids – aromatase inhibitors – fluoroquinolones – glucocorticoids – statins – tendon injury
Sources
1. FDA Drug Safety Communicatio: FDA updates warnings for oral and injectable fluorochinolone antibiotics due to disabling side effects. Dostupné z WWW: <http://www.fda.gov/Drugs/DrugSafety/ucm511530.htm>.
2. Lee HB. Avulsion and rupture of the tendo calcaneus after injection of hydrocortisone (letter). Br Med J 1957; 2(5041): 395.
3. Unverferth LJ, Olix ML. The effect of local steroid injections on tendon. J Sports Med 1973; 1(4): 31–37.
4. Newnham DM, Douglas JG, Legge JS et al. Achilles tendon rupture: an underrated complication of corticosteroid treatment. Thorax 1991; 46(11): 853–854.
5. Blanco I, Krähenbühl S, Schlienger RG. Corticosteroid-associated tendinopathies: an analysis of the published literature and spontaneous pharmacovigilance data. Drug Saf 2005; 28(7): 633–643.
6. Omar M, Haas P, Ettinger M et al. Simultaneous bilateral quadriceps tendon rupture following long-term low-dose nasal corticosteroid application. Case Rep Orthop 2013; 2013: 657845. Dostupné z DOI: <http://dx.doi.org/10.1155/2013/657845>.
7. Aydingöz U, Aydingöz O. Spontaneous rupture of the tibialis anterior tendon in a patient with psoriasis. Clin Imaging 2002; 26(3): 209–211.
8. Lee SK, Ling CM. The response of human tendon to hydrocortisone injection. Singap Med J 1975; 16(4): 259–262.
9. Poulsen RC, Carr AJ, Hulley PA. Protection against glucocorticoid-induced damage in human tenocytes by modulation of ERK, Akt and forkhead signaling. Endocrinology 2011; 152(2): 503–514. Dostupné z DOI: <http:///dx.doi.org/10.1210/en.2010–1087>.
10. Poulsen RC, Watts AC, Murphy RJ et al. Glucocorticoids induce senescence in primary human tenocytes by inhibition of sirtusin 1 and activation of the p53/p21 pathway: in vivo and in vitro evidence. Ann Rheum Dis 2014; 73(7): 1405–1413. Dostupné z DOI: <http://dx.doi.org/10.1136/annrheumdis-2012–203146>.
11. Chen W, Tang H, Zhou M et al. Dexamethasone inhibits the differentiation of rat tendon stem cells into tenocytes by targeting the scleraxis gene. J Steroid Biochem Mol Biol 2015; 152: 16–24. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jsbmb.2015.04.010>.
12. Spoendlin J, Meier C, Jick SS et al. Bisphosphonate therapy start may transiently increase the risk of tendon rupture in patients with glucocorticoid co-medication: a population-based observational study. Pharmacoepidemiol Drug Saf 2016; 25(10): 1116–1123. Dostupné z DOI: <http://dx.dorg/10.1002/pds.4042>.
13. Bailey RR, Kirk JA, Peddie BA. Norfloxacin-induced rheumatic disease. N Z Med J 1983; 96(736): 590.
14. McEwan SR, Davey PG. Ciprofloxacin and tenosynovitis. Lancet 1988; 2(8616): 900.
15. Khaliq Y, Zhanel GG. Fluoroquinolone- associated tendinopathy: a critical review of the literature. Clin Infect Dis 2003; 36(11): 1404–1410.
16. Shimatsu K, Subramaniam S, Sim H et al. Ciprofloxacin-induced tendinopathy of the gluteal tendons. J Gen Intern Med 2014; 29(11): 1559–1562. Dostupné z DOI: <http://dx.doi.org/10.1007/s11606–014–2960–4>.
17. Fraunfelder FW, Fraunfelder FT. Diplopia and fluoroquinolones. Ophthalmology 2009; 116(9): 1814–1817. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ophtha.2009.06.027>.
18. Tendon disorders with ofloxacin ear drops. Prescrire Int 2016; 25(169): 72.
19. Mafulli N, Sharma P, Luscombe KL. Achilles tendinopathy: aetiology and management. J R Soc Med 2004; 97(10): 472–476.
20. Aldred KJ, Kerns RJ, Osheroff N. Mechanism of quinolone action and resistence. Biochemistry 2014; 53(10): 1565–1574. Dostupné z DOI: <http://dx.doi.org/10.1021/bi5000564>.
21. Kato M, Takada S, Kashida I et al. Histological examination on Achilles tendon lesions induced by quinolone antibacterial agents in juvenile rats. Toxicol Pathol 1995; 23(3): 385–392.
22. Shakibaei M, Stahlmann R. Ultrastructure of Achilles tendon from rats after treatment with fleroxacin. Arch Toxicol 2001; 75(2): 97–102.
23. Simonin MA, Gegout-Pottie P, Minn A et al. Pefloxacin-induced Achilles tendon toxicity in rodents: biochemical changes in proteoglykan synthesis and oxidative damage to collagen. Antimicrob Agents Chemother 2000; 44(4): 867–872.
24. Tsai WC, Hsu CC, Chen HC et al. Ciprofloxacin-mediated inhibition of tenocyte migration and down-regulation of focal adhesion kinase phosphorylation. Eur J Pharmacol 2009; 607(1–3): 23–26. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ejphar.2009.02.006>.
25. Tsai WC, Hsu CC, Chen CP et al. Ciprofloxacin up-regulates tendon cells to express matrix metalloproteinase-2 with degradation of type I collagen. J Orthop Res 2011; 29(1): 67–73. Dostupné z DOI: <http://dx.doi.org/10.1002/jor.21196>.
26. Badal S, Her IF, Maher LJ. Nonantibiotic effects of fluorochinolones in mammalian cells. J Biol Chem 2015; 290(36): 22287–22297. Dostupné z DOI: <http://dx.doi.org/10.1074/jbc.M115.671222>.
27. Pamar C, Meda KP. Achilles tendon rupture associated with combination therapy of levofloxacin and steroid in four patients and a review of the literature. Foot Ankle Int 2007; 28(12): 1287–1289. Dostupné z DOI: <http://dx.doi.org/10.3113/FAI.2007.1287>.
28. Bidell MR, Lodise TP. Fluoroquinolone-associated tendinopathy: Does levofloxacin pose the greatest risk? Pharmacotherapy 2016; 36(6): 679–693. Dostupné z DOI: <http://dx.doi.org/10.1002/phar.1761>.
29. Chazerain P, Hayem G, Hamza S et al. Four cases of tendinopathy in patients on statin therapy. Joint Bone Spine 2001; 68(5): 430–433.
30. Marie I, Delafenetre H, Massy N et al. Tendinous disorders attributed to statins: A study on ninety-six spontaneous reports in the period 1990–2005 and review of the literature. Arthritis Rheum 2008; 59(3): 367–372. Dostupné z DOI: <http://dx.doi.org/10.1002/art.23309>.
31. De Oliveira LP, Vieira CP, Da Ré Guerra F et al. Statins induce biochemical changes in the Achilles tendon after chronic treatment. Toxicology 2013; 311(3): 162–168. Dostupné z DOI: <http://dx.doi.org/10.1016/j.tox.2013.06.010>.
32. Kuzma-Kuzniarska M, Cornell HR, Moneke MC et al. Lovastatin-mediated changes in human tendon cells. J Cell Physiol 2015; 230(10): 2543–2551. Dostupné z DOI: <http://dx.doi.org/10.1002/jcp.25010>.
33. 33.Teichtahl AJ, Brady SR, Urguhart DM et al. Statins and tendinopathy: a systematic review. Med J Aust 2016; 204(3): 115–121.
34. Contractor T, Beri A, Gardiner JC et al. Is statin use associated with tendon rupture? A population-based retrospective cohort analysis. Am J Ther 2015; 22(5): 337–381. Dostupné z DOI: <http://dx.doi.org/10.1097/MJT.0000000000000039>.
35. Lombard JM, Zdenkowski N, Wells K et al. Aromatase inhibitor induced musculosceletal syndrome: a significant problem with limited treatment options. Support Care Cancer 2016; 24(5): 2139–2146. Dostupné z DOI: <http://dx.doi.org/10.1007/s00520–015–3001–5>.
36. Nirawath P. Aromatase inhibitor-induced arthralgia: a review. Ann Oncol 2013; 24(6): 1443–1449. Dostupné z DOI: <http://dx.doi.org/10.1093/annonc/mdt037>.
37. Singer O, Cigler T, Moore AB et al. Defining the aromatase inhibitor musculosceletal syndrome: a prospective study. Arthritis Care Res (Hoboken) 2012; 64(12): 1910–1918. Dostupné z DOI: <http://dx.doi.org/10.1002/acr.21756>.
38. Lintermans A, Laenen A, Van Calster B et al. Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculosceletal syndrome: 2-year follow-up data. Ann Oncol 2013; 24(2): 350–355. Dostupné z DOI: <http://dx.doi.org/10.1093/annonc/mds290>.
39. Laroche M, Seniow M, Rahé H et al. Arthralgia associated with autoimmune abnormalities under aromatase inhibitor therapy: Outcome after cessation of treatment. J Rheumatol 2016; 43(10): 1945–1946.
40. Kirchgesner T, Larbi A, Omoumi P et al. Drug-induced tendinopathy: from physiology to clinical applications. Joint Bone Spine 2014; 81(6): 485–492. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jbspin.2014.03.022>.
41. Michna H. Tendon injuries induced by exercise and anabolic steroids in experimental mice. Int Orthop 1987; 11(2): 157–162.
42. Kanayama G, DeLuca J, Meehan WP et al. Ruptured tendons in anabolic-androgenic steroid users: A cros sectional cohort study. Am J Sport Med 2015; 43(11): 2638–2644. Dostupné z DOI: <http://dx.doi.org/10.1177/0363546515602010>.
43. Bottomley J, Cunliffe WJ. Acute Achilles tendonitis following oral isotretinoid therapy for acne vulgaris. Clin Exp Dermatol 1992; 17(4): 250–251.
44. Rodrigues IH, Allegue F. Achilles and suprapatellar tendinitis due to isotretinoin. J Rheumatol 1995; 22(10): 2009–2010.
45. Semira F, Wafai ZA, Khan U et al. Achilles tendinopathy as a rare adverse effect of oral isotretinoid treatment: two cases. IJGMP 2014; 3(4): 11–14.
46. Kalden JR, Schattenkirchner M, Sörensen H et al. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: A five-year followup study. Arth Rheum 2003; 48(6): 1513–1520.
47. FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. Dostupné z WWW:<http://www.fda.gov/Drugs/DrugSafety/ucm459579.htm>.
48. Bussey MR, Emanuele MA, Lomasney LM et al. Sitagliptin-induced bilateral Achilles tendinitis. Rheumatology 2013; 53(4): 630. Dostupné z DOI: <http://dx.doi.org/10.1093/rheumatology/ket395>.
49. Cresswell FV, Tomlins J, Churchill DR et al. Achilles tendinopathy following Kaletra (lopinavir/ritonavir) use. Int J STD AIDS 2014; 25(11): 833–835. Dostupné z DOI: <http://dx.doi.org/10.1177/0956462414523403>.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2017 Issue 12
Most read in this issue
- The current role of warfarin
- Citalopram and QT prolongation
- Drug induced tendon injury
- Unusual history of Wilson disease: a case report and review of the literature